Payer costs for COVID-19 ranged from a mean of $505 for asymptomatic cases to $126,094 for severe cases with post–COVID-19 condition.
This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.
This study examines the impact of geographically limited disasters on health care quality performance scores of Medicare Advantage contracts, finding limited impact on performance scores.
For Medicaid care management, focusing on rising-risk patients is more effective than targeting high-cost claimants, whose spending tends to decrease over time due to regression to the mean.
The authors describe a primary care–based diabetic retinopathy screening program incorporating telemedicine, strong health information technology engagement, and development of clinical informatics tools.
This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.
Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.
A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.
Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults.
This study attempts to identify the sources of the significant 2.5-fold variation found in home health expenditures, a possible indicator of inefficiency and waste.
Hospital care transition activity facilitates uptake of Medicare-reimbursed transitional care management, which is associated with lower spending and better patient outcomes.
This report highlights the unique challenges faced by home health programs in addition to discussing how technology and policy changes have helped the elderly homebound during the coronavirus disease 2019 (COVID-19) pandemic.
In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems.
The authors’ organization optimized scheduling techniques that improved patient access to pediatric specialists to within 7 calendar days for new patients.
The Diabetes Care Rewards program offers a business case for health plans to promote engagement through use of contingent incentives, thus improving health outcomes and lowering costs.
This article explores the congruence between payer patient assignment and quality performance and the implications for incentive payments in alternative payment models.
Mike Fazio, director of value-based care at Navista, Cardinal Health, discusses a trending topic at the 2025 Community Oncology Conference: optimizing oncology care with technology.
Pharmacists’ roles in transitions of care continue to evolve. Evaluation of pharmacist-led interventions as patients transition from emergency department to home is needed.
Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.
The European Respiratory Society (ERS) Congress fosters collaboration among global experts, advancing respiratory health and promoting equality in medicine.
This study evaluates the growth in electronic consultation use over the first 7 years after its implementation across the entire Veterans Health Administration system.
While treatment options are evolving cancer care and extending lifespans, there is still a lack of biomarkers in certain cancers that can help direct treatment or provide early detection.
The authors examine the origin, benefits, and challenges of pragmatic clinical trials to assess the ultimate value of this research design.
Procalcitonin test demand from the emergency department is growing, necessitating the implementation of strategies to address overuse. Successful interventions must be based on information technology.
The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.
Nicholas G. Anderson, MD; Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, provide insight on unmet needs and future directions for the treatment of wet AMD and DME.
Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.